Workflow
三诺生物: 关于回购股份注销完成调整可转换公司债券转股价格的公告

Core Points - The company has completed the adjustment of the conversion price for its convertible bonds following the repurchase and cancellation of shares [1][7][8] Group 1: Convertible Bond Issuance - The company issued 5 million convertible bonds with a total value of 500 million RMB, with an initial conversion price set at 35.35 RMB per share [1] - The bonds were approved by the China Securities Regulatory Commission and began trading on January 12, 2021 [1] Group 2: Conversion Price Adjustment Mechanism - The conversion price is subject to adjustments based on various corporate actions such as stock dividends, capital increases, and cash dividends, following specific formulas [2][3] - The adjustment formulas account for factors like stock dividend rates, new share issuance rates, and cash dividend amounts [2] Group 3: Historical Adjustments - The conversion price has undergone several adjustments due to corporate actions, including a reduction from 35.35 RMB to 35.15 RMB on June 11, 2021, following a cash dividend distribution [3][5] - Subsequent adjustments included changes to 34.98 RMB on May 25, 2022, and 34.81 RMB on May 26, 2023, due to similar corporate actions [5][6] Group 4: Recent Adjustments - Following the repurchase and cancellation of 3,999,287 shares, the total share capital decreased from 564,265,375 to 560,266,088 shares [7] - The conversion price was adjusted from 34.39 RMB to 34.46 RMB, effective from July 14, 2025, based on the repurchase price and the number of shares canceled [7][8]